CE-marked access MeMed BV brings rapid bacterial vs viral answers to the core lab

At ESCMID Global 2026, leaders from Danaher and Beckman Coulter Diagnostics unveiled a major milestone: the CE-marked European launch of the Access MeMed BV^® host response assay, bringing rapid bacterial vs viral differentiation to familiar core laboratory immunoassay platforms.

In this interview, Ephraim Tsalik (Chief Scientific Officer, Infectious Disease & Acute Care, Danaher) and Dr. Stephanie Mitchell (Senior Director, Infectious Diseases & Microbiology, Beckman Coulter Diagnostics) explain how host-response testing can integrate seamlessly into routine workflows on DxI 9000 and Access 2, delivering actionable results in around 20 minutes to support earlier, more confident clinical decisions.

You will also hear how the test was developed using omics and machine learning, and distilled into three biomarkers that generate a clear, interpretable score, helping clinicians address one of the most persistent challenges in infectious diseases, and strengthen antimicrobial stewardship and diagnostic pathways.

Interview recorded at ESCMID Global 2026.